N/A N=94 TAKE Steps: Motivational Interviewing to Prevent STIs
Self Efficacy · HIV Prevention · STI Prevention
Primary: Change in Prevention Self-efficacy — 1.87; 0.20 score on a scale — p=0.04
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=12 Fistula Reintegration Pilot
Female Genital Fistula · Urinary Incontinence
Primary: Percentage of Planned Intervention Sessions That Were Delivered — 96.2 percentage of planned sessions
Early Phase 1 N=8 Ultralow Dose PAH Binary Mixture Study
Environmental Exposure
Primary: Peak Plasma Concentration of 14C-BaP Cmax — 7.07; 1.60 fg [14C]-BaP/mL plasma
N/A N=13 MASC: Reducing Stress for Caregivers
Alzheimer Disease and Related Dementias · Dementia Alzheimers
Primary: Feasibility of Recruitment — 13; 4 Participants
Phase 2 N=396 Quit Smoking Study for People Who Use E-Cigarettes
Nicotine Addiction · E-Cig Use · Quitting Smoking
Primary: Biochemically Confirmed 7-day Point-prevalence Cigarette Abstinence — 16; 26; 16; 16 Participants
Phase 3 N=88 Impact on Glycemic Variability in Newly Onset T2DM Patients Initiating Dapagliflozin Plus Metformin Versus Metformin Alone
Type 2 Diabetes
Primary: ΔHbA1c — -1.8; -1.6 percentage of HbA1c
Phase 1 N=27 Effect of Selective Serotonin Reuptake Inhibitors (SSRIs) and an Opioid on Ventilation
Hypercapnia · Ventilatory Depression
Primary: Minute Ventilation at 55mm Hg End Tidal CO2 (VE55) Under Hyperoxic Conditions on Day 21 — 20.2; 21.2; 26.7 L/min — p=<0.001
N/A N=266 Actis Total Hip System 2 Year Follow-up
Osteoarthritis · Traumatic Arthritis · Rheumatoid Arthritis
Primary: Harris Hip Score- THA Subjects Per Protocol at 2 Years — 95.7 units on a scale
Early Phase 1 N=8 Benzo[a]Pyrene Ultralow Dose-Response Study
Environmental Exposure
Primary: Peak Plasma Concentration Cmax — 2.51; 5.68; 13.8; 8.99 fg [14C]-BaP/mL plasma
Phase 1 N=33 Behavioral Pharmacology of THC and Alpha-pinene
THC · Alpha-pinene
Primary: Mean Peak Change From Baseline Drug Effect as Assessed by the Drug Effect Questionnaire (DEQ) — -1.2; 5.1; 67.2; 66.1 score on a scale
N/A N=24 Clinical Study to Compare Two Skin Substitute Categories for Their Effectiveness to Treat Diabetic Foot Ulcers
Diabetic Foot Ulcer
Primary: Percentage of Wound Area Reduction — 83.9; 71.3 Percentage of Wound Area Reduction
N/A N=91 Mobile-enhanced Group CBT for Adolescents at Risk Severe Mood Disorders
Adolescents · Mood Disorders
Primary: Treatment Skill Practice — 16.1; 56.2; 44.3 treatment skill practices
N/A N=13 Compression Nail for Tibiocalcaneal Arthrodesis
Subtalar Arthritis · Ankle Arthritis
Primary: Pain Assessment — 52.73; 33.00; 17.00; 21.25 score on a scale
N/A N=139 Performance of Masimo INVSENSOR00057 in Detecting Atrial Fibrillation (Afib)
Atrial Fibrillation
Primary: Sensitivity of INVSENSOR00057 Atrial Fibrillation (Afib) Detection Function — 96.97 % of true positive
Phase 1 N=61 Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B
Hepatitis B
Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) — 9; 3; 7; 7 Participants